Children's Hospital of Michigan
Detroit, Michigan, 48201, United States
NCT Number: NCT02092883
The purpose of this study was to investigate the presence of neuroinflammation in children with infantile spasms using 11C-PK11195 positron emission tomography (PK PET) scan, and its response to ACTH treatment by repeating the PK PET scan after treatment.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 4
Detroit, Michigan, 48201, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PK PET scan before and after ACTH treatment
Time frame: up to 6 weeks
Neuroinflammation in cortical and/or subcortical structures of the brain in patients with Infantile Spasms will be evaluated with 11-C-PK11195 PET scan at the baseline and 2 weeks after the completion of ACTH treatment (given over 4 weeks), i.e., 6 weeks after the baseline PET scan.
Wayne State University
Other
Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06315829
Brain Diseases, Central Nervous System Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT00441896
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial DetailsNCT02954887
Brain Diseases, Central Nervous System Diseases
Little Rock, Arkansas, United States
View Trial DetailsNCT02953548
Brain Diseases, Central Nervous System Diseases
Little Rock, Arkansas, United States
View Trial Details